Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases.

[1]  K. Eguchi,et al.  A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab , 2012, Rheumatology International.

[2]  B. Gilson,et al.  [Pulmonary and renal involvement in a TNFα antagonist drug-induced sarcoidosis]. , 2012, La Revue de medecine interne.

[3]  R. Omdal,et al.  Development of sarcoidosis following etanercept treatment: a report of three cases , 2012, Rheumatology International.

[4]  J. Gómez-Reino,et al.  Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. , 2011, Seminars in arthritis and rheumatism.

[5]  X. Bosch,et al.  Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. , 2011, Seminars in arthritis and rheumatism.

[6]  M. Castells,et al.  Injection‐site reaction to etanercept: role of skin test in the diagnosis of such reaction and successful desensitization , 2011, Allergy.

[7]  G. D. Dal Pan,et al.  Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. , 2011, Journal of the American Academy of Dermatology.

[8]  P. Sfikakis,et al.  Biological treatments and connective tissue disease associated interstitial lung disease , 2011, Current opinion in pulmonary medicine.

[9]  Philip R. Cohen,et al.  TNF alpha antagonist‐induced lupus‐like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists , 2011, International journal of dermatology.

[10]  B. Dijkmans,et al.  Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. , 2011, JAMA.

[11]  D. Gladman,et al.  Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. , 2011, Arthritis and rheumatism.

[12]  R. Sanmartí,et al.  Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review. , 2011, Archivos de bronconeumologia.

[13]  S. Dourakis,et al.  Sarcoid-like granulomatosis in patients treated with anti-TNFα factors. A case report and review of the literature , 2011, Clinical Rheumatology.

[14]  P. Delaval,et al.  Sarcoïdose pulmonaire apparue sous étanercept , 2011 .

[15]  H. Léna,et al.  [Pulmonary sarcoidosis developing during treatment with etanercept]. , 2011, Revue des maladies respiratoires.

[16]  H. Yamanaka,et al.  Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis , 2011, Modern rheumatology.

[17]  F. Tubach,et al.  Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry , 2010, Annals of the rheumatic diseases.

[18]  D. Battafarano,et al.  Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. , 2010, Seminars in arthritis and rheumatism.

[19]  C. Roux,et al.  Reactivation of cutaneous psoriasis during abatacept therapy for spondyloarthropathy. , 2010, Joint, bone, spine : revue du rhumatisme.

[20]  H. Gröne,et al.  Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  M. Breban,et al.  Onset of psoriasis following treatment with tocilizumab , 2010, The British journal of dermatology.

[22]  J. Singh,et al.  Applying science in practice: the optimization of biological therapy in rheumatoid arthritis , 2010, Arthritis Research & Therapy.

[23]  T. Bouldin,et al.  A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab. , 2010, Arthritis and rheumatism.

[24]  J. O'dell,et al.  State-of-the-art: rheumatoid arthritis , 2010, Annals of the rheumatic diseases.

[25]  L. Heinzerling,et al.  Sarcoidosis Induced by Interferon-α in Melanoma Patients: Incidence, Clinical Manifestations, and Management Strategies , 2010, Journal of immunotherapy.

[26]  M. Khraishi,et al.  Safety profile of abatacept in rheumatoid arthritis: a review. , 2010, Clinical therapeutics.

[27]  M. Schiff.  Abatacept treatment for rheumatoid arthritis , 2010, Rheumatology.

[28]  A. Pink,et al.  The development of sarcoidosis on antitumour necrosis factor therapy: a paradox , 2010, The British journal of dermatology.

[29]  P. Limburg,et al.  The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis. , 2010, Clinical and experimental rheumatology.

[30]  M. Crow.  Type I interferon in organ-targeted autoimmune and inflammatory diseases , 2010, Arthritis research & therapy.

[31]  M. Péntek,et al.  Adherence to biologic DMARD therapies in rheumatoid arthritis , 2010, Expert opinion on biological therapy.

[32]  K. Ohashi,et al.  Development of myeloperoxidase-antineutrophil cytoplasmic antibody-associated renal vasculitis in a patient receiving treatment with anti-tumor necrosis factor-α , 2010, Modern rheumatology.

[33]  W. Mnif,et al.  Golimumab Therapy of Rheumatoid Arthritis: An Overview , 2010, Scandinavian journal of immunology.

[34]  G. Tobón,et al.  The environment, geo-epidemiology, and autoimmune disease: Rheumatoid arthritis. , 2010, Journal of autoimmunity.

[35]  C. V. van Gils,et al.  Risk factors for idiopathic orbital inflammation: a case–control study , 2010, British Journal of Ophthalmology.

[36]  Bill Pikounis,et al.  Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α , 2010, mAbs.

[37]  W. Pichler,et al.  The complex clinical picture of side effects to biologicals. , 2010, The Medical clinics of North America.

[38]  J. Keane,et al.  How tumour necrosis factor blockers interfere with tuberculosis immunity , 2010, Clinical and experimental immunology.

[39]  Timothy B. Niewold,et al.  Interferon Alpha in Systemic Lupus Erythematosus , 2010, Journal of biomedicine & biotechnology.

[40]  J. Pers,et al.  Emerging biotherapies for Sjögren's syndrome , 2010, Expert opinion on emerging drugs.

[41]  P. Visca,et al.  Pulmonary sarcoidosis in a patient with psoriatic arthritis during infliximab therapy. , 2010, Dermatology online journal.

[42]  Pietro Invernizzi,et al.  Geoepidemiology of autoimmune liver diseases. , 2010, Journal of autoimmunity.

[43]  E. Maverakis,et al.  Light, including ultraviolet. , 2010, Journal of autoimmunity.

[44]  Y. Shoenfeld,et al.  Effects of tobacco smoke on immunity, inflammation and autoimmunity. , 2010, Journal of autoimmunity.

[45]  Michael Schivo,et al.  Geoepidemiology of COPD and idiopathic pulmonary fibrosis. , 2010, Journal of autoimmunity.

[46]  Y. Shoenfeld,et al.  Defining and analyzing geoepidemiology and human autoimmunity. , 2010, Journal of autoimmunity.

[47]  Y. Tomer.  Hepatitis C and interferon induced thyroiditis. , 2010, Journal of autoimmunity.

[48]  J. Powell,et al.  Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. , 2010, Journal of autoimmunity.

[49]  K. Hemminki,et al.  The epidemiology of Graves' disease: evidence of a genetic and an environmental contribution. , 2010, Journal of autoimmunity.

[50]  J. Pers,et al.  Epigenetics and autoimmunity. , 2010, Journal of autoimmunity.

[51]  Ryan M. O’Connell,et al.  Coordination of tolerogenic immune responses by the commensal microbiota. , 2010, Journal of autoimmunity.

[52]  A. Matucci,et al.  Anti‐infliximab IgE and non‐IgE antibodies and induction of infusion‐related severe anaphylactic reactions , 2010, Allergy.

[53]  M. Gershwin,et al.  The implications of autoimmunity and pregnancy. , 2010, Journal of autoimmunity.

[54]  Christopher Chang.  The immune effects of naturally occurring and synthetic nanoparticles. , 2010, Journal of autoimmunity.

[55]  Y. Shoenfeld,et al.  Geo-epidemiology and autoimmunity. , 2010, Journal of autoimmunity.

[56]  M. Gershwin,et al.  Drugs and autoimmunity--a contemporary review and mechanistic approach. , 2010, Journal of autoimmunity.

[57]  Hidetoshi Takahashi,et al.  Sarcoidosis during infliximab therapy for Crohn’s disease , 2010, The Journal of dermatology.

[58]  Vinod Chandran,et al.  Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. , 2010, Journal of autoimmunity.

[59]  S. Muller,et al.  Nucleic acid-associated autoantigens: pathogenic involvement and therapeutic potential. , 2010, Journal of autoimmunity.

[60]  Min Chen,et al.  The complement system in systemic autoimmune disease. , 2010, Journal of autoimmunity.

[61]  M. Kawai,et al.  Minimal influence of tocilizumab on IFN-γ synthesis by tuberculosis antigens , 2010, Modern rheumatology.

[62]  E. Bonfá,et al.  Immunogenicity of Anti-TNF-α Agents in Autoimmune Diseases , 2010, Clinical reviews in allergy & immunology.

[63]  H. Moutsopoulos,et al.  The geoepidemiology of Sjögren's syndrome. , 2010, Autoimmunity reviews.

[64]  M. Gershwin,et al.  The geoepidemiology of immune thrombocytopenic purpura. , 2010, Autoimmunity reviews.

[65]  E. Kahana,et al.  Multiple sclerosis: geoepidemiology, genetics and the environment. , 2010, Autoimmunity reviews.

[66]  S. Padeh,et al.  Environmental factors and the geoepidemiology of juvenile idiopathic arthritis. , 2010, Autoimmunity reviews.

[67]  R. Uibo,et al.  The geoepidemiology of type 1 diabetes. , 2010, Autoimmunity reviews.

[68]  L. Mouthon,et al.  Geoepidemiology of systemic sclerosis. , 2010, Autoimmunity reviews.

[69]  C. Bowlus,et al.  The geoepidemiology of autoimmune intestinal diseases. , 2010, Autoimmunity reviews.

[70]  J. Grau,et al.  The geoepidemiology of autoimmune muscle disease. , 2010, Autoimmunity reviews.

[71]  M. Ehrenfeld.  Geoepidemiology: the environment and spondyloarthropathies. , 2010, Autoimmunity reviews.

[72]  M. Tao,et al.  Development and validation of gene therapies in autoimmune diseases: Epidemiology to animal models. , 2010, Autoimmunity reviews.

[73]  Ljudmila Stojanovich,et al.  Stress and autoimmunity. , 2010, Autoimmunity reviews.

[74]  Pietro Invernizzi,et al.  Definition of human autoimmunity--autoantibodies versus autoimmune disease. , 2010, Autoimmunity reviews.

[75]  P. Meroni,et al.  The geoepidemiology of the antiphospholipid antibody syndrome. , 2010, Autoimmunity reviews.

[76]  U. Nydegger,et al.  Geoepidemiology of autoimmune hemolytic anemia. , 2010, Autoimmunity reviews.

[77]  N. Meyer,et al.  Geoepidemiologic considerations of auto-immune pemphigus. , 2010, Autoimmunity reviews.

[78]  M. Segelmark,et al.  Autoimmune kidney diseases. , 2010, Autoimmunity reviews.

[79]  J. Tuscano,et al.  Geoepidemiology and autoimmune manifestations of lymphoproliferative disorders. , 2010, Autoimmunity reviews.

[80]  Min Chen,et al.  The environment, geoepidemiology and ANCA-associated vasculitides. , 2010, Autoimmunity reviews.

[81]  M. Gershwin,et al.  The epidemiology of transverse myelitis. , 2010, Autoimmunity reviews.

[82]  K. Tsuneyama,et al.  Nutrition, geoepidemiology, and autoimmunity. , 2010, Autoimmunity reviews.

[83]  C. Selmi.  The worldwide gradient of autoimmune conditions. , 2010, Autoimmunity reviews.

[84]  Y. Levy,et al.  Geoepidemiology of myasthenia gravis [corrected]. , 2010, Autoimmunity reviews.

[85]  I. Mackay.  Travels and travails of autoimmunity: a historical journey from discovery to rediscovery. , 2010, Autoimmunity reviews.

[86]  Y. Shoenfeld,et al.  The geoepidemiology of systemic lupus erythematosus. , 2010, Autoimmunity reviews.

[87]  P. Boumier,et al.  Cutaneous Sarcoidosis Occurring during Anti-TNF-Alpha Treatment: Report of Two Cases , 2010, Dermatology.

[88]  S. Yamasaki,et al.  Cutaneous vasculitis induced by TNF inhibitors: a report of three cases , 2010, Modern rheumatology.

[89]  L. Cavazzini,et al.  Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review. , 2010, Seminars in arthritis and rheumatism.

[90]  B. Dijkmans,et al.  Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment , 2010, Arthritis research & therapy.

[91]  M. Iwamoto,et al.  Abrupt Development of Sarcoidosis with a Prodromal Increase in Plasma Osteopontin in a Patient with Rheumatoid Arthritis During Treatment with Etanercept , 2010, The Journal of Rheumatology.

[92]  C. Ding,et al.  Tocilizumab: A Review of Its Safety and Efficacy in Rheumatoid Arthritis , 2010, Clinical medicine insights. Arthritis and musculoskeletal disorders.

[93]  L. Calabrese,et al.  Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. , 2009, Arthritis and rheumatism.

[94]  G. Braunstahl,et al.  Sarcoidosis During Anti-Tumor Necrosis Factor-α Therapy: No Relapse After Rechallenge , 2009, The Journal of Rheumatology.

[95]  S. Lepreux,et al.  Cytokine imbalance with increased production of interferon‐α in psoriasiform eruptions associated with antitumour necrosis factor‐α treatments , 2009, The British journal of dermatology.

[96]  M. Cottone,et al.  Severe Cutaneous Psoriasis After Certolizumab Pegol Treatment: Report of a Case , 2009, The American Journal of Gastroenterology.

[97]  M. Davis,et al.  Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. , 2009, Mayo Clinic proceedings.

[98]  S. Pavy,et al.  Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. , 2009, Rheumatology.

[99]  S. Suissa,et al.  Demyelinating events in rheumatoid arthritis after drug exposures , 2009, Annals of the rheumatic diseases.

[100]  B. Séroussi,et al.  Rituximab-induced lung disease: a systematic literature review , 2009, European Respiratory Journal.

[101]  D Emilie,et al.  Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. , 2009, Arthritis and rheumatism.

[102]  J. Moreau,et al.  Myeloid dendritic cells correlate with clinical response whereas plasmacytoid dendritic cells impact autoantibody development in rheumatoid arthritis patients treated with infliximab , 2009, Arthritis research & therapy.

[103]  M. Khraishi.  Comparative Overview of Safety of the Biologics in Rheumatoid Arthritis , 2009, The Journal of Rheumatology.

[104]  David Green,et al.  Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. , 2009, Blood.

[105]  R. Rabin,et al.  Anaphylactic Reaction to Anakinra in a Rheumatoid Arthritis Patient Intolerant to Multiple Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs , 2009, The Annals of pharmacotherapy.

[106]  P. Dieudé,et al.  Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. , 2009, Joint, bone, spine : revue du rhumatisme.

[107]  A. Saraux,et al.  Critical analysis of rituximab-induced serological changes in connective tissue diseases. , 2009, Autoimmunity reviews.

[108]  C. Lacroix,et al.  Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. , 2009, Archives of neurology.

[109]  D. Arkfeld,et al.  Adalimumab-induced noncaseating granuloma in the bone marrow of a patient being treated for rheumatoid arthritis , 2009, Rheumatology International.

[110]  E. Zimlichman,et al.  The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. , 2008, Journal of autoimmunity.

[111]  P. V. van Riel,et al.  Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis , 2008, Annals of the rheumatic diseases.

[112]  T. Therneau,et al.  Systemic Lupus Erythematosus Features in Rheumatoid Arthritis and Their Effect on Overall Mortality , 2008, The Journal of Rheumatology.

[113]  J. Aguillón,et al.  Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis. , 2008, Clinical and experimental rheumatology.

[114]  M. Khamashta,et al.  Autoimmune diseases induced by TNF-targeted therapies. , 2008, Best practice & research. Clinical rheumatology.

[115]  B. Dijkmans,et al.  Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. , 2008, The Journal of rheumatology.

[116]  J. Mikdashi,et al.  Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab. , 2008, Archives of dermatology.

[117]  C. Wijbrandts,et al.  Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade , 2008, Annals of the rheumatic diseases.

[118]  J. W. Pendleton,et al.  Demyelinating disease associated with use of etanercept in patients with seronegative spondyloarthropathies. , 2008, The Journal of rheumatology.

[119]  J. Ménard,et al.  Impact of Three Anti-TNFα Biologics on Existing and Emergent Autoimmunity in Rheumatoid Arthritis and Spondylarthropathy Patients , 2008, Journal of Clinical Immunology.

[120]  E. Rewald,et al.  A Propos Time and Autoimmunity , 2008, Clinical reviews in allergy & immunology.

[121]  B. Zimmermann,et al.  Drug-Induced Lupus due to Anti-Tumor Necrosis Factor α Agents , 2008 .

[122]  M. Dougados,et al.  Comparison of the clinical characteristics of vasculitis occurring during anti-tumor necrosis factor treatment or not in rheumatoid arthritis patients. A systematic review of 2707 patients, 18 vasculitis. , 2008, Clinical and experimental rheumatology.

[123]  J. Val-Bernal,et al.  New‐onset psoriasis following treatment with the interleukin‐1 receptor antagonist anakinra , 2008, The British journal of dermatology.

[124]  Takahiko Horiuchi,et al.  Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. , 2008, Arthritis and rheumatism.

[125]  T. Ishida,et al.  A case of rheumatoid arthritis complicated by demyelination in both cerebral cortex and spinal cord during etanercept therapy , 2008, Modern rheumatology.

[126]  W. Dixon,et al.  Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register , 2008, Annals of the rheumatic diseases.

[127]  J. Swarowska-Knap,et al.  Neurological disorders with demyelinating brain white matter lesions in a patient with rheumatoid arthritis treated with etanercept. , 2008, Polskie Archiwum Medycyny Wewnetrznej.

[128]  F. Breedveld,et al.  An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status , 2008, Clinical Rheumatology.

[129]  D. Owen,et al.  Granulomatous hepatitis associated with etanercept therapy. , 2008, The Journal of rheumatology.

[130]  R. Dodge,et al.  Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis. , 2007, The Journal of rheumatology.

[131]  S. Pillemer,et al.  Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept. , 2007, Arthritis and rheumatism.

[132]  M. Dougados,et al.  Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. , 2007, Arthritis and rheumatism.

[133]  J. Val-Bernal,et al.  Recall injection‐site reactions associated with etanercept therapy: report of two new cases with immunohistochemical analysis , 2007, Clincal and Experimental Dermatology.

[134]  A. Nesbitt,et al.  Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti‐tumor necrosis factor &agr; agents , 2007, Inflammatory bowel diseases.

[135]  J. Meca-Lallana,et al.  Multiple Sclerosis Onset during Etanercept Treatment , 2007, European Neurology.

[136]  P. Demoly,et al.  Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-α antagonists , 2007, Current opinion in allergy and clinical immunology.

[137]  P. Emery,et al.  Development of psoriasis after B cell depletion with rituximab. , 2007, Arthritis and rheumatism.

[138]  H. Yamanaka,et al.  Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[139]  M. Khamashta,et al.  Autoimmune Diseases Induced by TNF-Targeted Therapies: Analysis of 233 Cases , 2007, Medicine.

[140]  N. Bizzaro,et al.  Interpretative comments on autoantibody tests. , 2007, Autoimmunity reviews.

[141]  Nicola Bizzaro,et al.  Are we at a stage to predict autoimmune rheumatic diseases? , 2007, Arthritis and rheumatism.

[142]  R. Wallis.  Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma. , 2007, The journal of investigative dermatology. Symposium proceedings.

[143]  H. Erdem,et al.  Optic neuritis occurring with anti-tumour necrosis factor α therapy , 2007 .

[144]  P. Richette,et al.  Psoriasis induced by anti-tumor necrosis factor therapy: a class effect? , 2007, The Journal of rheumatology.

[145]  M. Martinka,et al.  Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. , 2007, Archives of dermatology.

[146]  D. Deleu,et al.  Central nervous system demyelination associated with etanercept in a 51 years old woman , 2007, The Libyan journal of medicine.

[147]  I. Sezer,et al.  Adverse effect of TNF‐alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report , 2006, Journal of clinical pharmacy and therapeutics.

[148]  M. Broder,et al.  Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. , 2006, Seminars in arthritis and rheumatism.

[149]  M. Bandt,et al.  Vasculitides induced by TNFα antagonists: a study in 39 patients in France , 2006 .

[150]  J. Jagirdar,et al.  Sarcoidosis after treatment with interferon-α: A case series and review of the literature , 2006 .

[151]  B. Sands,et al.  A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. , 2006, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[152]  Shunsuke Kobayashi,et al.  New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients , 2006, Clinical Rheumatology.

[153]  R. Wallis,et al.  Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. , 2006, The Journal of infectious diseases.

[154]  R. Peek,et al.  Psoriasis after treatment of juvenile idiopathic arthritis with etanercept , 2006, Annals of the rheumatic diseases.

[155]  A. Silman,et al.  Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. , 2006, Arthritis and rheumatism.

[156]  W. Pichler.  Adverse side‐effects to biological agents , 2006, Allergy.

[157]  M. Humbert,et al.  Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists , 2006, Arthritis research & therapy.

[158]  Nawar Al Saieg,et al.  Etanercept induced multiple sclerosis and transverse myelitis. , 2006, The Journal of rheumatology.

[159]  L. Provinciali,et al.  CNS demyelination during anti–tumor necrosis factor alpha therapy , 2006, Journal of Neurology.

[160]  Yaakov Naparstek,et al.  Autoimmunity in the era of genomics and proteomics. , 2006, Autoimmunity reviews.

[161]  T. Horn,et al.  Eosinophilic cellulitislike reaction to subcutaneous etanercept injection. , 2006, Archives of dermatology.

[162]  G. Burmester,et al.  Safety of extended treatment with anakinra in patients with rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[163]  J. Val-Bernal,et al.  Demyelinating disease and cutaneous lymphocitic vasculitis after etanercept therapy in a patient with rheumatoid arthritis , 2006, Scandinavian journal of rheumatology.

[164]  P. Sarzi-Puttini,et al.  Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study , 2005, Arthritis research & therapy.

[165]  G. Burmester,et al.  Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis , 2005, Annals of the rheumatic diseases.

[166]  Matthias Schneider,et al.  Infections in patients with rheumatoid arthritis treated with biologic agents. , 2005, Arthritis and rheumatism.

[167]  R. González-Amaro,et al.  Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis , 2005, Clinical and experimental immunology.

[168]  C. Kittas,et al.  Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. , 2005, Arthritis and rheumatism.

[169]  I. Mackay.  The etiopathogenesis of autoimmunity. , 2005, Seminars in liver disease.

[170]  O. Boyman,et al.  Plasmacytoid predendritic cells initiate psoriasis through interferon-α production , 2005, The Journal of experimental medicine.

[171]  L. Jacobsson,et al.  Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. , 2005, Arthritis and rheumatism.

[172]  D. Baeten,et al.  Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. , 2005, Arthritis and rheumatism.

[173]  C. Tsai,et al.  The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis , 2005, Annals of the rheumatic diseases.

[174]  P. Anderson.  Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. , 2005, Seminars in arthritis and rheumatism.

[175]  V. Pascual,et al.  Cross-regulation of TNF and IFN-¿ in autoimmune diseases , 2005 .

[176]  N. Martinelli,et al.  Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment , 2005, Rheumatology International.

[177]  P. Jüni,et al.  Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors. , 2005, Rheumatology.

[178]  T. Horiuchi,et al.  Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. , 2005, Gastroenterology.

[179]  P. Rutgeerts,et al.  Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept , 2005, Alimentary pharmacology & therapeutics.

[180]  C. Deighton,et al.  Delayed multiple injection site reaction in a rheumatoid arthritis patient treated with etanercept. , 2004, Rheumatology.

[181]  M. Broder,et al.  Granulomatous infections due to tumor necrosis factor blockade: correction. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[182]  M. Braun,et al.  Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. , 2004, The Journal of rheumatology.

[183]  L. Mouthon,et al.  Tumor necrosis factor-alpha blockade and the risk of vasculitis. , 2004, The Journal of rheumatology.

[184]  J. Bienvenu,et al.  Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study , 2004, Arthritis research & therapy.

[185]  W. Robinson,et al.  Demyelination and inhibition of tumor necrosis factor (TNF). , 2004, Clinical and experimental rheumatology.

[186]  S. Rantapää-Dahlqvist,et al.  Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFα , 2004, Annals of the rheumatic diseases.

[187]  P. Miossec,et al.  Effect of treatment of rheumatoid arthritis with infliximab on IFNγ, IL4, T-bet, and GATA-3 expression: link with improvement of systemic inflammation and disease activity , 2004, Annals of the rheumatic diseases.

[188]  E. Veys,et al.  Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis , 2004, Annals of the rheumatic diseases.

[189]  O. Vaarala,et al.  Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis , 2004, Annals of the rheumatic diseases.

[190]  R. Caporali,et al.  Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment , 2004, Arthritis research & therapy.

[191]  L. Klareskog,et al.  Treatment with tumour necrosis factor α antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies , 2004, Annals of the rheumatic diseases.

[192]  J. Casanova,et al.  Association between IFNA genotype and the risk of sarcoidosis , 2004, Human Genetics.

[193]  M. Gershwin,et al.  Clinical and immunologic components of sarcoidosis , 2003, Clinical reviews in allergy & immunology.

[194]  P. Emery,et al.  Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. , 2003, The Journal of rheumatology.

[195]  V. Pascual,et al.  The central role of dendritic cells and interferon-&agr; in SLE , 2003 .

[196]  J. Gómez-Reino,et al.  Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. , 2003, Arthritis and rheumatism.

[197]  Pilar Barrera,et al.  Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. , 2003, Arthritis and rheumatism.

[198]  D. Schroeder,et al.  Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. , 2003, Chest.

[199]  D. Hommes,et al.  Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. , 2003, Gastroenterology.

[200]  A. Thiel,et al.  Up regulation of the production of tumour necrosis factor α and interferon γ by T cells in ankylosing spondylitis during treatment with etanercept , 2003 .

[201]  E. Veys,et al.  Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. , 2003, Arthritis and rheumatism.

[202]  A. Schuerwegh,et al.  Influence of therapy with chimeric monoclonal tumour necrosis factor-alpha antibodies on intracellular cytokine profiles of T lymphocytes and monocytes in rheumatoid arthritis patients. , 2003, Rheumatology.

[203]  A. Thiel,et al.  Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. , 2003, Arthritis and rheumatism.

[204]  O. Meyer,et al.  Anti-TNF-α-induced systemic lupus syndrome , 2003, Clinical Rheumatology.

[205]  J. Braun,et al.  Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment. , 2002, Clinical and experimental rheumatology.

[206]  Xiao-Yu Song,et al.  Binding and functional comparisons of two types of tumor necrosis factor antagonists. , 2002, The Journal of pharmacology and experimental therapeutics.

[207]  S. Deventer,et al.  Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease , 2002, Gut.

[208]  J. Richert,et al.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. , 2001, Arthritis and rheumatism.

[209]  W Domschke,et al.  Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. , 2001, Gastroenterology.

[210]  Joseph Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent , 2001 .

[211]  M. De Vos,et al.  Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFα , 2001, Annals of the rheumatic diseases.

[212]  C. Ritchlin,et al.  Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. , 2001, Archives of dermatology.

[213]  A. Levinson,et al.  Etanercept-induced injection site reactions: mechanistic insights from clinical findings and immunohistochemistry. , 2001, Archives of dermatology.

[214]  L. Klareskog,et al.  Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFα receptors , 2001, Annals of the rheumatic diseases.

[215]  M. Feldmann,et al.  Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. , 2000, Arthritis and rheumatism.

[216]  F. Breedveld,et al.  Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis. , 1999, Arthritis and rheumatism.

[217]  M. Yamaguchi,et al.  The frequency of sarcoidosis in Finland and Hokkaido, Japan. A comparative epidemiological study. , 1995, Sarcoidosis.

[218]  A. Cope,et al.  Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. , 1994, The Journal of clinical investigation.

[219]  A. Steinberg,et al.  Cyclophosphamide: use in practice. , 1974, Annals of internal medicine.

[220]  J. Kadota,et al.  Adalimumab-induced interstitial pneumonia with an improvement of pre-existing rheumatoid arthritis-associated lung involvement. , 2011, Internal medicine.

[221]  R. Sanmartí,et al.  Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review. , 2011 .

[222]  L. Espinoza,et al.  Tumor necrosis factor-alpha (TNF-α)-blockade-induced hepatic sarcoidosis in psoriatic arthritis (PsA): case report and review of the literature , 2010, Clinical Rheumatology.

[223]  M. Khamashta,et al.  Autoimmune diseases induced by biological agents: a double-edged sword? , 2010, Autoimmunity reviews.

[224]  C. Wijbrandts,et al.  Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis. , 2010, Rheumatology.

[225]  D. Loeuille,et al.  Arterial and venous thromboembolic events during anti-TNF therapy: a study of 85 spontaneous reports in the period 2000-2006. , 2009, Bio-medical materials and engineering.

[226]  P. Kahn.  Juvenile idiopathic arthritis--current and future therapies. , 2009, Bulletin of the NYU hospital for joint diseases.

[227]  J. Valat,et al.  Adalimumab-associated multiple sclerosis. , 2007, The Journal of rheumatology.

[228]  L. Klareskog,et al.  Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. , 2005, Arthritis and rheumatism.

[229]  W. Dixon,et al.  Extended Report , 2022 .